Speaking with @karenjagoda of the Empowered Patient Podcast, CMO Dr. Tram Tran discusses how Glympse’s #diagnostic platform simplifies things in the clinic and for the patient using a simple blood-based test.
Listen to the podcast here: https://t.co/bcfmRo9AnG
Glympse is developing #technology that can non-invasively measure protein activity to #diagnose and monitor disease.
Learn more by viewing the animation on our website: https://t.co/6kG0wU61ZC
Watch: Dr. Amit Singal (@docamitgs) of @utswcancer discusses the need for early #HCC diagnosis and the #TLM22 data demonstrating that Glympse's biosensor platform can sensitively detect HCC.
https://t.co/abrY3EsBPk
#TLM22 begins today!
Glympse and Dr. Amit Singal (@docamitgs) will present a poster on Monday 11/7 from 1-2 PM that demonstrates our biosensors can sensitively detect HCC. We hope to see you then!
You can view the poster on our website: https://t.co/heer0q3Pls
@AASLDtweets
Glympse will present a poster at @AASLDtweets#TLM22 demonstrating the sensitive detection of #HCC by our novel diagnostic platform.
You can see the poster on Monday, Nov. 7 from 1-2 PM and find more information in our announcement: https://t.co/fYMiGN624d
A recent @HealioGastro article highlights how #NASH is the fastest growing cause of hepatocellular carcinoma (#HCC) in the US and of #livercancer deaths worldwide.
Glympse’s platform and diagnostic potential seeks to help reverse this trend.
https://t.co/hQkzkywOcc
October is #LiverAwarenessMonth. Liver disease takes many forms and can significantly impact a patient's quality of life. Glympse is dedicated to developing diagnostics to help improve treatments for patients with #liverdisease.
Learn more from @liverUSA: https://t.co/csV2T7u6tV
#ICYMI, our #CMO Tram Tran, MD, wrote an article for @Tech_Networks about the burden of #liverdisease on the healthcare system and the role #diagnostics like Glympse’s can play in alleviating this.
Read Tram’s article here: https://t.co/IqCTPBusBy
Shout out to our new #CSO, Dr. Jonathan Wilde! Since joining the team earlier this year, Dr. Wilde’s scientific expertise has been integral in the development of our novel protein activity biosensor #diagnostic platform.
On this week’s episode of @PharmaVoice’s #WomanOfTheWeek podcast, CMO Dr. Tram Tran shares the inspirations that led to her career path in #medicine and work on Glympse’s revolutionary diagnostic technology.
Listen to the full episode here: https://t.co/pYvmCQF2IV
CMO Dr. Tram Tran sat down with @MyDocWire to discuss Glympse’s focus on early disease detection for #NASH and improving patient outcomes with its unique protein activity-based diagnostic platform.
Watch: https://t.co/lreInCMgyv
Tomorrow, June 24, Dr. Amit Singal (@docamitgs) will present findings at #ILC2022 demonstrating that #Glympse’s biosensor platform can detect #HCC from non-HCC patients with liver cirrhosis from a blood sample.
See the poster here: https://t.co/sGyiJvXZsI
On Saturday, June 25, CMO Tram Tran, M.D. will present a poster at @EASLNews’s #ILC2022 demonstrating our novel protease biosensor diagnostic platform’s ability to distinguish NASH vs. healthy patients from a blood sample.
See the poster here: https://t.co/R2n5vo9vgg
#Glympse CMO @TramTran_MD spoke with @AnnetteMBoyle of @BioWorld about our @EASLnews#ILC2022 data demonstrating early detection of #HCC from a simple blood test and the importance of this for patients.
Read more: https://t.co/xyrtTSqBbH
Today is International #NASHDay. NASH is a severe form of fatty #liverdisease that affects millions worldwide. At #Glympse, we are developing technologies to improve how we diagnose and monitor NASH, so we can #StopNASHNow.
Learn more from @globalliver: https://t.co/XW7jZyua9T
#Glympse will present two posters on the accuracy of its protease biosensor diagnostic platform in detecting patients with hepatocellular carcinoma (#HCC) at the @EASLnews International Liver Congress 2022 #ILC2022.
Find out more: https://t.co/uF3d1Jxk7F